These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15479863)

  • 1. Advances in Targeted Therapies VI. Proceedings of the 6th International Symposium. Venice, Italy, 28 April-2 May 2004.
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2():ii1-101. PubMed ID: 15479863
    [No Abstract]   [Full Text] [Related]  

  • 2. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of the XIIth International Symposium on Advances in Targeted Therapies. April 14-18, 2010.
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1-122. PubMed ID: 21438187
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings from the XIth International Symposium on Advances in Targeted Therapies, 22 to 26 April 2009.
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i1-99. PubMed ID: 20310079
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in targeted therapies X. Preface.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii1. PubMed ID: 19022807
    [No Abstract]   [Full Text] [Related]  

  • 6. Advances in targeted therapies VIII. Proceedings of the Eighth International Symposium on Advances in Targeted Therapy. April 5-9, 2006. Sorrento, Italy.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii1-89. PubMed ID: 17038463
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunogenicity of TNF alpha inhibitors in rheumatology: many questions, enough answers?
    Wendling D; Verhoeven F; Guillot X; Prati C
    Expert Opin Drug Saf; 2017 Jan; 16(1):1-3. PubMed ID: 27737601
    [No Abstract]   [Full Text] [Related]  

  • 8. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
    Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216
    [No Abstract]   [Full Text] [Related]  

  • 9. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in targeted therapies XII. Preface.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i1. PubMed ID: 21339210
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in targeted therapies XI.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i1. PubMed ID: 19995739
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in targeted therapies XIII.
    Breedveld FC; Kalden JR; Smolen JS
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i1. PubMed ID: 22460135
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel immunological targets in rheumatic diseases: clues from current therapies.
    D'Acquisto F; Rattazzi L; Piras G; Galuppo ML
    Drug Discov Today; 2014 Aug; 19(8):1155-60. PubMed ID: 24984284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction.
    Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):1. PubMed ID: 27924647
    [No Abstract]   [Full Text] [Related]  

  • 15. Proceedings of the Seventh International Symposium on Advances in Targeted Therapy. April 6-10, 2005. Venice, Italy.
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv1-108. PubMed ID: 16239375
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanism of action of tumor necrosis factor antagonists. Proceedings of the Canadian expert roundtable meeting, Banff, Canada, November 28-30, 2003.
    J Rheumatol Suppl; 2005 Mar; 74():1-47. PubMed ID: 15742456
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in targeted therapies IV. Proceedings of the Fourth International Symposium. Mandelieu, France. April 28-May 1, 2002.
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2():ii1-103. PubMed ID: 12379611
    [No Abstract]   [Full Text] [Related]  

  • 18. Advances in targeted therapies V: Proceedings of the 5th International Symposium. St Martin, French West Indies. 11-14 April 2003.
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2():ii1-96. PubMed ID: 14532137
    [No Abstract]   [Full Text] [Related]  

  • 19. Actual status of antiinterleukin-1 therapies in rheumatic diseases.
    Geyer M; Müller-Ladner U
    Curr Opin Rheumatol; 2010 May; 22(3):246-51. PubMed ID: 20150813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on prescribing tumor necrosis factor inhibitors.
    Hanauer LB
    Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.